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ORIGINAL RESEARCH
Dynamic Susceptibility MR Perfusion in
Diagnosing Recurrent Brain Metastases
After Radiotherapy: A Systematic Review
and Meta-Analysis
Robert M. Kwee, MD, PhD,1 and Thomas C. Kwee, MD, PhD2*
Background: The diagnostic performance of dynamic susceptibility contrast (DSC) MR perfusion in discriminating treatment-
related changes from recurrence in irradiated brainmetastases is currently not completely clear.
Purpose: To systematically review the accuracy of DSC MR perfusion in diagnosing recurrent brain metastases after
radiotherapy.
Study Type: Systematic review and meta-analysis.
Subjects: MEDLINE and Embase were searched for original studies investigating the accuracy of DSC MR perfusion in
diagnosing recurrent brain metastases after radiotherapy. Ten studies, comprising a total of more than 271 metastases,
were included.
Field Strength/Sequence: 1.5T or 3.0T, DSC MR perfusion.
Assessment: Quality assessment was performed according to the Quality Assessment of Diagnostic Accuracy Studies-
2 tool.
Statistical Tests: Sensitivity and specificity were pooled with a bivariate random-effects model. Heterogeneity was assessed
by a chi-squared test. Potential sources for heterogeneity were explored by subgroup analyses.
Results: In seven studies the diagnostic criterionwas not prespecified. In eight studies it was unclear whether the reference stan-
dard was interpreted blindly. In seven studies it was unclear whether DSCMR perfusion results influenced which reference stan-
dard was used. Pooled sensitivity and specificity were 81.6% (95% confidence interval [CI]: 70.6%, 89.1%) and 80.6% (95% CI:
64.2%, 90.6%), respectively. There was significant heterogeneity in both sensitivity (P = 0.005) and specificity (P < 0.001). There
were no significant differences in relative diagnostic odds ratio according to publication year, country of origin, study size, and
DSC MR perfusion interpretation method (visual analysis of cerebral blood volume [CBV] map vs. relative CBV measurement)
(P > 0.2). Due to insufficiently detailed reporting, it was not possible to investigate the influence of primary tumor origin on
accuracy.
Data Conclusion: Our results suggest that the accuracy of DSC MR perfusion in diagnosing recurrent brain metastases
after radiotherapy is fairly high. However, these findings should be interpreted with caution because of methodological
quality concerns and heterogeneity between studies.
Level of Evidence: 3
Technical Efficacy: Stage 2
J. MAGN. RESON. IMAGING 2020;51:524–534.
BRAIN METASTASES are the most common malignantintracranial neoplasms in adults.1 They occur in ~2% of
all patients with newly diagnosed invasive solid cancer.2
Because of increased surveillance and improved systemic con-
trol, the incidence is likely to grow.1 Brain metastases are
associated with significant morbidity and mortality.2 Current
care involves stereotactic or whole-brain radiotherapy and/or
surgery, depending on the number, size, and site of metasta-
ses, as well as overall systemic disease control and patient’s
performance status.1
An estimated one-third of brain metastases increase in size
after irradiation and the longer the patient survives, the more likely
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an increase in lesion size will be seen on follow-up imaging.3 This
increase in size occurs secondary to blood–brain barrier disruption
with accumulation of paramagnetic agents in the extracellular
space and is nonspecific4,5: it can represent either treatment-
related changes (pseudoprogression or radionecrosis) or metastatic
recurrence. Because of the similar appearance, they are difficult to
discriminate on conventional contrast-enhanced magnetic reso-
nance imaging (MRI).4–6 Accordingly, lesion measurements on
conventional postgadolinium T1-weighted and T2-weighted
images are not significantly associated with either treatment-
related changes or metastatic recurrence.5 One study suggested
that the ratio of the lesion as seen on T2-weighted images to the
total enhancing area on postgadoliniumT1-weighted images could
be useful,7 but a later independent study found this so-called
lesion quotient not to be discriminative, with sensitivity and speci-
ficity of only 59% and 41%, respectively.5 However, early and
accurate diagnosis is important, since patients with treatment-
related changes can undergo watchful waiting, whereas patients
with metastatic recurrence are potential candidates for surgery or
repeated stereotactic radiotherapy.8,9 Histopathologic confirma-
tion is the current gold standard,5 but biopsy/surgery is invasive,
with potential complications such as hemorrhage and infection.10
There is therefore a need for a noninvasive tool that can accurately
diagnose recurrent brain metastases after radiotherapy. Dynamic
susceptibility contrast (DSC) MR perfusion may be used to dis-
criminate treatment-related changes from metastatic recur-
rence.11,12 DSC MR perfusion uses the first-pass susceptibility
effect of a gadolinium-based contrast agent within the intravascu-
lar compartment.11,12 It allows assessment of several hemody-
namic imaging variables. The relative cerebral blood volume
(rCBV) is the most widely used hemodynamic variable derived
from DSC MR perfusion and has been shown to correlate with
primary glioma tumor grade and tumor microvascular den-
sity.11,12 rCBV is generally elevated in viable or recurrent metasta-
ses after radiotherapy but not in treatment-related changes11,12
(Figs. 1–2). However, the diagnostic performance of DCS MR
perfusion is currently not completely clear. Therefore, the purpose
of this study was to systematically review the accuracy of DCS




A search in MEDLINE and Embase was conducted to find publica-
tions on the accuracy of DSC MR perfusion in diagnosing recurrent
brain metastases after radiotherapy. The following search terms were
used: (brain OR cerebral OR intracranial) AND (metastases OR
metastasis OR metastatic) AND (magnetic resonance OR MR imag-
ing OR MRI OR magnetic resonance tomography OR nuclear mag-
netic resonance OR NMR) AND (perfusion OR dynamic OR
susceptibility OR DSC). The search was updated until October
2018. Bibliographies of studies which finally remained after the
selection process were screened for potentially suitable references.
Study Selection
Original studies investigating the accuracy of DSC MR perfusion in
diagnosing recurrent brain metastases after radiotherapy were eligible for
inclusion. Studies involving ≤10 patients with brain metastases were
excluded. Studies that only investigated the accuracy of dynamic
contrast-enhanced MR perfusion (relying on T1 shortening due to
gadolinium-based contrast) or arterial spin labeling were excluded. Stud-
ies that only assessed change in DSC MR perfusion before and after
radiotherapy as a predictor of tumor response were also excluded. Studies
that provided insufficient data to construct a 2 × 2 contingency table to
calculate sensitivity and specificity were also excluded. With the use of
the aforementioned selection criteria, titles and abstracts of retrieved
studies were reviewed. Full-text versions of potentially eligible articles
were retrieved. Full-text articles were then reviewed to definitively deter-
mine if the study was eligible for inclusion.
FIGURE 1: Pseudoprogression of brain metastasis from nonsmall-cell lung cancer in the right parietotemporal region in a 60-year-old
woman. Axial contrast-enhanced T1-weighted image 6 months after stereotactic radiotherapy (b) shows increased size of the
contrast-enhancing lesion compared with 3 months before (a). At the CBV map 6 months after stereotactic radiotherapy (c) no
highly vascularized areas within the contrast-enhancing lesion are seen, indicative of pseudoprogression. Further follow-up showed
decreasing size of the lesion (MR images not shown), confirming pseudoprogression.
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Study Data Extraction
For each included study, principle characteristics (Table 1) and true pos-
itive, false positive, false negative, and true negative values of DSC MR
perfusion in diagnosing recurrent brain metastases were extracted.
Study Quality Assessment
Study quality was assessed by using the Quality Assessment of
Diagnostic Accuracy Studies 2 (QUADAS-2) tool, which comprises four
key domains: "patient selection," "index test," "reference standard," and
"flow and timing."13
Statistical Analyses
Sensitivity and specificity of individual studies were calculated. A bivari-
ate random-effects model was used for meta-analysis.9 Individual studies
were plotted in receiver operating characteristic (ROC) space, as were
the summary estimate with 95% confidence ellipse.14 A chi-squared test
was performed to test for heterogeneity. Potential sources for heteroge-
neity were explored by assessing whether certain covariates significantly
influenced the relative diagnostic odds ratio (RDOR).15 Prespecified
covariates were publication year (published before vs. in or after 2013
[2013 was the median]), country of origin (USA vs. other countries),
study size (<28 vs. >28 patients [28 was the median]), andDSCMRper-
fusion interpretation method (visual analysis of CBV map vs. rCBV
measurement). In studies that performed both visual analysis of CBV
map and rCBV measurement, we compared the area under the ROC
curve (AUC) for bothmethods.16 Potential publication bias was assessed
by a funnel plot.17 Statistical analyses were performed using Meta-
analysis of Diagnostic Accuracy Studies package in R software18,19 and
MedCalc Statistical Software, v. 15.8 (MedCalc Software, Ostend, Bel-
gium). P < 0.05 was considered statistically significant for all analyses.
Results
Literature Search
The study selection process is displayed in Fig. 3. Fifteen studies
were potentially eligible for inclusion.8,11,20–32 After reviewing
the full text, one study was excluded because the accuracy of
DSC MR perfusion was not investigated24; two studies were
excluded because only a change in DSC MR perfusion before
and after radiotherapy as predictor of metastatic tumor response
was assessed,31,32 one study was excluded because it provided
insufficient data for a 2 × 2 contingency table,27 and one study
was excluded because no separable data on the accuracy of DSC
MR perfusion were reported.25 Eventually, 10 studies were
included.8,11,20–23,26,28–30
The median number of patients per study was 28 (range
15–46). DSCMR perfusion data were available on 271 metasta-
ses. The median prevalence of recurrent brain metastases was
56.9% (range 7.7%–83.3%).
Methodologic Quality Assessment
QUADAS-2 assessments are displayed in Table 2 and summarized
in Fig. 4. Risk of bias with respect to patient selection was rated
"unclear" in two studies5,28,30 because it was unclear whether a
consecutive or random sample was enrolled and whether there
were no inappropriate exclusions. Risk of bias with respect to index
test was rated "high" in seven studies11,20–22,26,28,29 because
diagnostic criteria were not prespecified. Risk of bias with
respect to reference standard was rated "unclear" in eight
studies,8,11,20,22,23,26,28,29 because it was unclear whether the refer-
ence standard was interpreted without knowledge of the results of
DSC MR perfusion. Risk of bias with respect to flow and timing
was rated "unclear" in seven studies11,20,22,23,26,28,30 because it was
unclear whether DSC MR perfusion results influenced the deci-
sion which reference standard was used. Risk of bias with respect
to flow and timing was rated "high" in one study,8 because not all
patients were included in the analysis. In two studies,22,23 there
were applicability concerns with respect to patient selection,
because both stable and progressive metastases at conventional
MR (contrast-enhanced T1-weighted MR images) were included.
There were no other applicability concerns.
Diagnostic Performance
Different diagnostic criteria were used (Table 1). Both sensi-
tivity and specificity from individual studies ranged from 0%
FIGURE 2: Recurrent metastasis originating from nonsmall-cell lung cancer in the left occipital lobe in a 69-year-old man. Axial
contrast-enhanced T1-weighted image 6 months after stereotactic radiotherapy (b) shows increased size of the contrast-enhancing
lesion compared with 3 months before (a). At the CBV map 6 months after stereotactic radiotherapy (c) highly vascularized areas
within the contrast-enhancing lesion are seen, indicative of recurrence. The lesion was subsequently resected and histopathological
analysis confirmed metastatic recurrence.
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to 100% (Fig. 5), with pooled estimates of 81.6% (95% con-
fidence interval [CI]: 70.6%, 89.1%) and 80.6% (95% CI:
64.2%, 90.6%), respectively. The ROC plot is shown in
Fig. 6. The AUC was 0.873. All studies, except Muto et al’s
study,22 reported accuracy data on a per-lesion basis. Muto
et al’s study22 used number of MR examinations (mean of
2.69 per patient) for accuracy analysis. Excluding this study22
from meta-analysis resulted in pooled sensitivity of 79.4%
(95% CI: 68.6%, 87.2%) and pooled specificity of 77.3%
(95% CI: 61.6%, 87.9%), with an AUC of 0.847.
The median percentage of uninterpretable lesions per
study was 5.35 (range 0–20.0) (Table 1). In one study,30 six
lesions were excluded from accuracy analysis because visual
CBV map analysis was nonconclusive.
The included studies were heterogeneous in sensitivity
(P = 0.005) and specificity (P < 0.001). RDORs were not sig-
nificantly different in subgroups according to publication
year, country of origin, study size, and DSC MR perfusion
interpretation method (Table 3). In the only included study
that performed both visual analysis of the CBV map and
rCBV measurement,30 AUCs did not significantly differ:
AUC of 0.813 (95% CI: 0.621, 0.934) for visual analysis of
CBV map vs. AUC of 0.754 (95% CI, 0.556, 0.896) for
rCBV measurement (P = 0.6167).
FIGURE 3: Flowchart of the study selection process. *All 15 potentially relevant studies were found in both databases.
TABLE 2. QUADAS-2 Assessment Results of Each of the Included Studies
















Wang et al20 Low High Unclear Unclear Low Low Low
Knitter et al21 Low High Low Low Low Low Low
Muto et al22 Low High Unclear Unclear High Low Low
Kerkhof al.23 Low Unclear Unclear Unclear High Low Low
Cicone et al26 Low High Unclear Unclear Low Low Low
Huang et al28 Low High Unclear Unclear Low Low Low
Mitsuya et al29 Low High Unclear Low Low Low Low
Hoefnagels et al30 Unclear Low Low Unclear Low Low Low
Barajas et al11 Low High Unclear Unclear Low Low Low
Truong et al8 Unclear Unclear Unclear High Low Low Low
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The funnel plot (Fig. 7) was roughly symmetrical,
suggesting a low likelihood of publication bias.
Discussion
This systematic review investigated the accuracy of DSCMR per-
fusion in diagnosing recurrent brain metastases after radiotherapy.
Different diagnostic criteria were used by the included studies to
define metastatic recurrence. We used a bivariate random-effects
model for meta-analysis, which acknowledges a possible threshold
effect.14 Pooled sensitivity and specificity were fairly high, but
there was significant between-study heterogeneity.
Potential bias in the domains "index test," "reference
standard," and "flow and timing" may have resulted in over-
estimation of accuracy. In clinical practice, DSCMR perfusion is
typically used to differentiate treatment-related changes from
recurrence in irradiated metastases which show a new area of
enhancement and/or enlargement at conventional MR. There
FIGURE 4: Summary of QUADAS-2 assessments of the 10 included studies.
FIGURE 5: Forest plots of sensitivity and specificity of included studies. aabsolute CBV; brCBV; cAt 3 months follow-up; dAt 6 months
follow-up; eSubjective scoring of CBV map; frCBV (maximum CBV lesion/mean CBV NACWM); grCBV (maximum CBV lesion/mean
CBV NACGM).
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were applicability concerns with respect to patient selection in
two studies,22,23 because they included both stable and progres-
sive metastases at conventional MR. However, DSC MR perfu-
sion may also have value in metastases that show stability or
regression at conventional MR, because changes in tumor physi-
ology may precede structural changes.
DSC MR perfusion can be performed on any modern MR
scanner, has a short acquisition time, and postprocessing software
is widely available.33 However, it has some inherent limitations.
Blood products or melanin within brain metastases can cause a sig-
nificant degree of susceptibility artifacts, impeding assessment.11,23
Furthermore, metastases may not be evaluable if they are too small
or near large vessels or bone.23 In this systematic review, the
median percentage of uninterpretable lesions was 5.35%.
The studies thatmeasured rCBV showed variation in region
of interest (ROI) placement: ROIs were placed encompassing the
entire contrast-enhancing lesion21,22,26 or in selected areas of the
contrast-enhancing lesion,8,11,20,29 whereas in some studies the
method of ROI placement was not described.28,30 Some studies
measuredmean values, whereas other studies measuredmaximum
values. The mean value varies depending on which voxels are
included in the average, making it sensitive to ROI definition.
The maximum value is less dependent on ROI definition (assum-
ing the voxel with highest CBV and no normal macrovessels are
included) but more susceptible to noise. Only two of the included
studies reported interobserver reproducibility.20,22 Wang et al20
reported good interobserver agreement for mean rCBV. Muto
et al22 also reported good interobserver agreement, but did not
specify whether this applied to mean or maximum rCBV. Fur-
thermore, it has recently been shown that ROI placement in the
semioval center as reference tissue provides the highest inter-
observer agreement.34 However, only one of the included studies
reported using the semioval center as reference tissue.30 One other
study used the normal-appearing contralateral white matter
(NACWM) on the same transaxial plane as the lesion as reference
tissue,11 whereas in the other studies8,20–22,26,28,29 the exact loca-
tion of ROI placement in the NACWMwas not reported.
Exploratory subgroup analyses suggested that publication
year, country of origin, study size, and DSCMR perfusion inter-
pretation methods were no causes of heterogeneity. ROC curve
analysis of the only included study that performed both visual
analysis of CBVmap and rCBVmeasurement30 also showed that
diagnostic accuracy between both perfusion interpretation
methods was not significantly different. Pretreatment rCBV of
brain metastases from renal carcinoma and melanoma are signifi-
cantly higher than rCBV of brain metastases from lung, breast,
and gastrointestinal carcinoma.35,36 Furthermore, it has been
shown by microscopy that neovascularization patterns of brain
FIGURE 6: Receiver operating characteristic plot. *Individual
study data (small triangles) have been plotted in ROC space, as
were the summary estimate (small circle) with 95% confidence
ellipse (oval area, thin line) and summary receiver operating
characteristic curve (thick line). *From Wang et al’s study,20
rCBV data were used; from Kerkhof et al’s study,23 3-month
follow-up data were used; and from Hoefnagels et al’s study,30
data from visual CBV map analysis were used for analysis. SROC:
summary receiver operating characteristic curve; conf. region:
95% confidence ellipse of pooled sensitivity and specificity.
TABLE 3. Subgroup Analyses
Parameter Variablesa
Relative diagnostic
odds ratiob P value
Publication year Published after (5) vs. published
before 2013 (5)
2.21 (0.14, 34.01) 0.5157
Country of origin USA (6) vs. Other countries (4) 0.21 (0.01, 2.92) 0.2030
Study size >28 patients (5) vs. <28 (5) 1.88 (0.11, 31.20) 0.6101
DSC MR perfusion
interpretation method
Visual analysis of CBV map (2) vs.
measurement of rCBV (7)
0.22 (0.01, 8.93) 0.3554
aData in parentheses are number of studies.
bData in parentheses are 95% CIs.
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metastases from a different origin can be quite different. For
instance, neovascularization is a specific hallmark of nonsmall-
cell lung cancer metastases, whereas melanoma metastases show
less neovascularization and more perivascular growth along pre-
existing vascular structures.37 Therefore, one may expect that the
diagnostic performance of DSC MR perfusion differs consider-
ably among different tumor entities. However, all included stud-
ies pooled metastases of different primary tumor origin together,
so it was not possible to investigate the influence of primary
tumor origin on accuracy. Another potential source of heteroge-
neity is the use of different definitions for recurrent metastases in
studies using histopathology as the reference standard. Other
potential sources of heterogeneity are variations in MR parame-
ters (such as the use of preload, leakage correction, injection rate,
flip angle, and temporal coverage), postprocessing methods (for
leakage correction), and diagnostic criteria. Unfortunately, due
to large variability between studies, we could not perform mean-
ingful subgroup analyses for these parameters.
This systematic review has some limitations. First, the
number of included studies was relatively low. Therefore, we
could not fully explore potential sources of heterogeneity with
subgroup analysis or meta-regression. Second, the funnel plot
which suggested the absence of publication bias is not always
a reliable tool.38,39
Conventional MRI findings of treatment-related changes
and metastatic recurrence overlap considerably.4–6 Therefore,
DSC MR perfusion can be a very useful adjunct in diagnosing
recurrent brain metastases after radiotherapy. However, pooled
sensitivity and specificity of DSCMR perfusion were fairly high,
but not perfect. Furthermore, it is still questionable whether
these pooled overall results can be applied to all metastases of dif-
ferent primary origin and there is no uniformly accepted diagnos-
tic criterion yet. Therefore, one should be careful to make clinical
decisions based on DSC MR perfusion results alone. The ques-
tion remains as to what represents "best practice" based on
current evidence. We suggest that DSC MR perfusion acquisi-
tions are performed according to recommendations from the
American Society of Functional Neuroradiology (ASFNR).12
According to the ASFNR, preload administration of a single con-
trast agent bolus with postprocessing leakage correction and
implicit correction of T1 leakage effects with a dual-echo acquisi-
tion methodology are the two methods that best distinguish
rCBV in tumor from normal brain in the presence of contrast
agent leakage effects.12 We suggest that either one of these
methods is used.We found no evidence that either visual analysis
of CBV maps or rCBV measurements performed better than the
other in terms of diagnostic accuracy. Therefore, at present it
may be justified to use either one of these perfusion interpreta-
tion methods. We believe that all MRI results should be inter-
preted in the clinical context (including patient symptoms and
clinical findings, date and type of treatment received, and sys-
temic status). This is preferably discussed in a neuro-oncology
multidisciplinary team meeting, which is the optimal place to
make decisions regarding further diagnostic work-up (such as
closer follow-up or stereotactic biopsy) and treatment.40,41
In order to validate DSCMR perfusion for clinical applica-
tion, it is essential to further investigate potential causes of hetero-
geneity. Ideally, this is done by prospective studies following
ASFNR recommendations regarding DSCMR perfusion acquisi-
tion and postprocessing. Future studies shouldmake a direct com-
parison between DSC MR perfusion interpretation methods and
perform stratified analysis for metastases per primary tumor type.
Diagnostic accuracy may be improved by combining DSC MR
perfusion with other advancedMR techniques25 or positron emis-
sion tomography,42,43 but this also needs further investigation.
In conclusion, the results of our study suggest that the
accuracy of DSC MR perfusion in diagnosing recurrent brain
metastases after radiotherapy is fairly high. However, these
findings should be interpreted with caution because of meth-
odological quality concerns and heterogeneity between stud-
ies. There is no uniformly accepted diagnostic criterion to
define metastatic recurrence yet. Potential causes of heteroge-
neity need to be further investigated.
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